10-Q: Sangamo Faces Going Concern Doubt Amid Funding Woes

Sangamo Therapeutics reports improved Q2 2025 financials driven by new collaborations but warns of substantial doubt about its ability to continue as a going concern.

Summary

• Net loss significantly decreased to $19.986 million for Q2 2025, down from $36.128 million in Q2 2024, and to $50.583 million for H1 2025, down from $85.217 million in H1 2024.
• Revenues surged to $18.306 million in Q2 2025 from $0.356 million in Q2 2024, primarily due to an $18.0 million upfront payment from Eli Lilly and a $5.0 million payment from Pfizer.
• Cash and cash equivalents stood at $38.344 million as of June 30, 2025, with an estimated cash runway only into the fourth quarter of 2025.
• The company has initiated Phase 1/2 STAND study for ST-503 (idiopathic small fiber neuropathy) with first patient dosing expected in Fall 2025 and preliminary efficacy data in Q4 2026.
• Clinical Trial Application (CTA) enabling activities for ST-506 (prion disease) are advancing, with CTA submission expected as early as mid-2026.
• Positive topline results were reported from the Phase 1/2 STAAR study for isaralgagene civaparvovec (Fabry disease), showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52-weeks.
• All 32 Fabry disease patients transitioned to a long-term follow-up study, and the STAAR study is complete.
• The collaboration agreement with Pfizer for hemophilia A terminated on April 21, 2025, with Sangamo receiving a $5.0 million sublicense transfer payment and now seeking a new partner for the program.
• The company continues to engage in business development discussions for a commercialization agreement for its Fabry disease program but has been unsuccessful to date.
• Sangamo received a Nasdaq deficiency notice on April 30, 2025, for its common stock bid price falling below $1.00, with a compliance deadline of October 27, 2025.
• The company completed an underwritten offering in May 2025, raising $21.1 million in net proceeds, and sold additional shares through its at-the-market offering program, raising $8.9 million subsequent to June 30, 2025.

Sentiment

Score: 2

Explanation: Despite some positive clinical data and revenue growth from new collaborations, the explicit 'going concern' warning, extremely short cash runway, failure to secure a Fabry commercialization partner, and the mention of exploring bankruptcy protection indicate a dire financial situation and extremely negative sentiment.

Positives

• Significant increase in revenues for Q2 2025 ($18.306 million vs. $0.356 million in Q2 2024) and H1 2025 ($24.743 million vs. $0.837 million in H1 2024), driven by new collaboration agreements.
• Secured an $18.0 million upfront license payment from Eli Lilly in April 2025 for the STAC-BBB capsid, with potential for up to $1.4 billion in additional fees and milestones.
• Received a $5.0 million payment from Pfizer related to the hemophilia A sublicense transfer.
• Reported positive topline results from the registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (Fabry disease), including a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52-weeks.
• FDA has agreed that the eGFR slope will serve as an intermediate clinical endpoint under the Accelerated Approval pathway for Fabry disease.
• Patients in the Fabry disease study maintained elevated alpha-galactosidase A activity for up to 4.5 years and showed stabilization in cardiac endpoints.
• All Fabry disease patients who started on Enzyme Replacement Therapy (ERT) were able to safely withdraw from ERT, with most remaining off ERT.
• Observed improvements in quality of life scores (SF-36) and gastrointestinal symptoms (GSRS) in Fabry disease patients.
• Isaralgagene civaparvovec demonstrated a favorable safety and tolerability profile without the need for preconditioning.
• Advancement of core preclinical neurology programs, including initiation of clinical site for ST-503 (iSFN) and productive regulatory meeting for ST-506 (prion disease).
• Reduced net loss for both the three and six months ended June 30, 2025, compared to the same periods in 2024.
• Reduced net cash used in operating activities to $44.3 million for H1 2025, down from $75.5 million in H1 2024.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern for at least the next 12 months.
• Cash and cash equivalents of $38.344 million as of June 30, 2025, combined with subsequent ATM proceeds, are only sufficient to meet liquidity requirements into the fourth quarter of 2025.
• Unsuccessful in consummating a commercialization partner for the Fabry disease program to date, which substantially impairs the ability to raise additional capital.
• The Pfizer collaboration for hemophilia A terminated for convenience, requiring Sangamo to seek a new partner for the program.
• Received a Nasdaq deficiency notice for failing to meet the minimum bid price requirement, risking delisting if compliance is not regained by October 27, 2025.
• The company is exploring whether filing for bankruptcy protection is in the best interest of the company and its stakeholders.
• Future sales and issuances of equity securities would result in substantial dilution to stockholders, especially given the current stock price decline.
• The speculative nature of newly reprioritized core neurology preclinical programs and the absence of partners for more advanced clinical programs make attracting new investments difficult.
• Research and development expenses are expected to increase in the near-term due to BLA readiness activities for the Fabry disease program and advancement of other R&D programs, requiring substantial additional capital.

Risks

• Substantial doubt about the ability to continue as a going concern due to significant losses, negative cash flows, limited liquidity, and dependence on additional financing.
• Inability to secure a commercialization partner for the Fabry disease program in a timely manner or on acceptable terms, which would substantially impair the ability to raise additional capital.
• Risk of delisting from the Nasdaq Capital Market due to failure to meet the minimum bid price requirement, which could adversely affect stock liquidity and market price, and impair capital raising.
• Future sales and issuances of equity securities would result in substantial dilution to stockholders.
• Inability to attract new investments due to the speculative nature of newly reprioritized core neurology preclinical programs and the absence of partners for more advanced clinical programs.
• Potential requirement to cease operations entirely, liquidate assets, or seek protection under the U.S. Bankruptcy Code if adequate funds are not available.
• Reliance on external partners for manufacturing clinical supply for the neurology portfolio.
• Biotechnology and genomic medicine are highly competitive businesses, with competitors potentially developing superior or faster-commercialized technologies.
• The manufacture, storage, and transport of product candidates are complex, expensive, highly regulated, and risky.
• Even if product development is successful and regulatory approvals are obtained, products may not gain market acceptance.
• Difficulties in obtaining, maintaining, and enforcing patent protections, or involvement in patent/intellectual property lawsuits.
• Difficulties in hiring, integrating, and retaining qualified skilled employees.
• Unfavorable global economic conditions, including political instability, conflicts, trade issues, and inflation, could negatively impact operations and capital raising.
• Disruptions at the FDA, including workforce reductions or inadequate funding, could prevent timely review and approval of submissions, or changes in FDA policies could adversely impact development and approval pathways (e.g., Accelerated Approval program).

Future Outlook

The company estimates its current cash and cash equivalents, along with recent at-the-market offering proceeds, will only fund operations into the fourth quarter of 2025. It anticipates continued operating losses for the foreseeable future and expects research and development expenses to increase in the near-term due to Fabry disease BLA readiness and advancement of other R&D programs. The company is actively seeking substantial additional capital through collaborations, direct investments, or equity/debt financing to fund operations and progress its preclinical and clinical programs, including securing a commercialization partner for its Fabry disease program. Failure to secure adequate funding could lead to further cost reductions, delays, discontinuation of R&D activities, or potentially ceasing operations entirely and exploring bankruptcy protection. The company plans to dose the first patient in the ST-503 iSFN study in Fall 2025, with preliminary efficacy data anticipated in Q4 2026, and expects to submit a CTA for ST-506 (prion disease) as early as mid-2026. A Biologics License Application (BLA) submission for isaralgagene civaparvovec (Fabry disease) under the Accelerated Approval pathway is anticipated as early as Q1 2026.

Management Comments

• "We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies."
• "Based on our current operating plan, we estimate that our cash and cash equivalents as of June 30, 2025, together with $8.9 million generated through our at-the-market offering program since June 30, 2025, will be sufficient to meet our liquidity requirements only into the fourth quarter of 2025."
• "Our history of significant losses, negative cash flows from operations, limited liquidity resources currently on hand and dependence on our ability to obtain substantial additional financing to fund our operations have resulted in managements assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued."
• "We are engaged in business development discussions with potential counterparties concerning a commercialization agreement for our Fabry disease program, but have been unsuccessful in consummating any such transaction to date."
• "There can be no assurance that we will be able to secure a commercialization partner for our Fabry disease program in a timely manner, on acceptable terms, or at all, and if the Company is unable to execute such an agreement in the near term, our ability to raise additional capital needed to support our operations will be substantially impaired."
• "If adequate funds are not available to us on a timely basis, or at all, we will be required to take significant additional actions to address our liquidity needs, including substantial additional cost reduction measures such as further reducing operating expenses and further delaying, reducing the scope of, altering or discontinuing entirely our research and development activities, which would have a material adverse effect on our business and prospects, or we may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment."
• "We have explored, and will continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders."
• "We believe these data support the potential for isaralgagene civaparvovec as a one-time, durable treatment for Fabry disease that can improve patient outcomes and will form the basis for an anticipated Biologics License Application, or BLA, submission under the Accelerated Approval pathway as early as the first quarter of 2026."

Industry Context

Sangamo Therapeutics is operating within the highly competitive and capital-intensive genomic medicine and biotechnology sectors. The company's strategic shift to neurology-focused epigenetic regulation and AAV capsid delivery aligns with a growing industry trend towards precision medicine for complex neurological disorders. However, the industry faces significant challenges, including lengthy and expensive development cycles, high regulatory hurdles, and intense competition. The company's reliance on collaborations for funding and program advancement is common in the biotech space, but the termination of key partnerships (Pfizer, Kite, Biogen, Novartis) and the inability to secure a commercialization partner for its most advanced program (Fabry disease) highlight the inherent risks and difficulties in this model. Macroeconomic conditions, including financial instability and market volatility, are also impacting the ability of emerging biotechnology companies to access capital, exacerbating Sangamo's liquidity challenges.

Comparison to Industry Standards

• The positive eGFR slope of 1.965 mL/min/1.73m2/year at 52-weeks for isaralgagene civaparvovec in Fabry disease is a key metric. For context, the natural history of Fabry disease often shows a decline in eGFR, with some studies indicating an average annual decline of 2-4 mL/min/1.73m2 in untreated males. Enzyme Replacement Therapy (ERT) aims to stabilize or slow this decline. The observed positive slope suggests potential for improvement or significant stabilization, which could be competitive with or superior to current ERT standards, though direct comparative trials are needed.
• The ability of all patients on ERT to safely withdraw from treatment post-isaralgagene civaparvovec dosing is a significant clinical benefit, potentially reducing treatment burden compared to lifelong ERT regimens (e.g., Sanofi's Fabrazyme or Takeda's Replagal).
• The stabilization of cardiac endpoints (e.g., LVM, LVEF) is crucial, as cardiac complications are a major cause of morbidity and mortality in Fabry disease. This outcome, if durable, would compare favorably to the progressive cardiac damage often seen in untreated or suboptimally treated patients.
• The company's cash runway into Q4 2025 is extremely short, falling significantly below the typical 12-18 month runway often sought by biotech companies to avoid 'going concern' warnings and maintain investor confidence. This is a critical deviation from industry best practices for financial stability.
• The failure to secure a commercialization partner for the Fabry disease program, despite positive Phase 1/2 data and FDA's Accelerated Approval pathway agreement, is a notable concern. In the biotech industry, successful clinical data often attracts partnerships for late-stage development and commercialization, especially for rare diseases. This suggests potential challenges in deal terms, market perception, or the company's overall financial viability that deter partners.
• The Nasdaq delisting risk due to bid price non-compliance is a severe issue, as maintaining listing standards is fundamental for public companies to access capital markets and maintain investor liquidity. Many comparable small-cap biotechs face this challenge, but it signals significant investor concern and can further impair fundraising efforts.

Stakeholder Impact

• **Shareholders**: Face substantial dilution risk from future equity raises, potential loss of investment if the company ceases operations or files for bankruptcy, and reduced liquidity/market price if delisted from Nasdaq.
• **Employees**: Impacted by past restructurings (France, November 2023) with job eliminations, and potential for further workforce reductions or cessation of operations if funding is not secured.
• **Customers/Collaboration Partners**: Existing partners (Lilly, Astellas, Genentech, Alexion) may face uncertainty regarding Sangamo's long-term viability and ability to fulfill its obligations, though their agreements are structured to transfer responsibility for development. Potential new partners for Fabry disease and hemophilia A are deterred by the 'going concern' risk.
• **Suppliers/Creditors**: Face increased risk of non-payment or delayed payments if the company's financial condition deteriorates further or if it seeks bankruptcy protection.
• **Patients**: Development of promising therapies (e.g., Fabry disease, iSFN, prion disease) could be delayed, reduced in scope, or discontinued entirely, impacting access to potential treatments.

Next Steps

• Secure substantial additional capital through collaborations, direct investments, or equity/debt financing to continue operations.
• Dose the first patient in the Phase 1/2 STAND study for ST-503 (idiopathic small fiber neuropathy) in Fall 2025.
• Present updated nonclinical data for ST-503 at the 9th International Congress on Neuropathic Pain (September 4-6, 2025).
• Present additional clinical data for Fabry disease at the 15th International Congress of Inborn Errors of Metabolism (September 2-6, 2025).
• Regain compliance with Nasdaq's minimum bid price requirement by October 27, 2025, to avoid delisting.
• Anticipate preliminary proof of efficacy data for ST-503 in Q4 2026.
• Submit a Biologics License Application (BLA) for isaralgagene civaparvovec (Fabry disease) under the Accelerated Approval pathway as early as Q1 2026.
• Submit a Clinical Trial Application (CTA) for ST-506 (prion disease) as early as mid-2026.
• Continue long-term follow-up for clinical studies in France for previously dosed patients.
• Complete the remaining close-out costs for the Brisbane, California facility related to the November 2023 Restructuring within the next one to two years.

Key Dates

Recommendation

The filing explicitly states 'substantial doubt about our ability to continue to operate as a going concern' and that the company is 'exploring whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.' This, combined with a very short cash runway (into Q4 2025) and the failure to secure a commercialization partner for its most advanced program (Fabry disease) despite positive clinical data, indicates an extremely high risk of financial distress or failure. While there are positive clinical updates and new collaboration revenues, these are severely overshadowed by the existential threat to the company's operations. Investors face imminent and substantial risk of capital loss, making a 'strong sell' recommendation appropriate.

Keywords

Genomic Medicine, Biotechnology, Neurology, Fabry Disease, Gene Therapy, Epigenetic Regulation, AAV Capsid, STAC-BBB, ST-920, Isaralgagene Civaparvovec, Idiopathic Small Fiber Neuropathy, Prion Disease, ST-503, ST-506, Clinical Trials, Preclinical Development, FDA Accelerated Approval, BLA Submission, Going Concern, Capital Raise, Nasdaq Delisting, Collaboration Agreements, Eli Lilly, Pfizer, Astellas, Genentech, Hemophilia A, Restructuring, Financial Results